Literature DB >> 17364282

Impact of subclinical chorioamnionitis on maternal and neonatal outcomes.

Ken Miyazaki1, Madoka Furuhashi, Keitaro Matsuo, Kojiro Minami, Kana Yoshida, Naohiko Kuno, Kaoru Ishikawa.   

Abstract

BACKGROUND: Chorioamnionitis is considered to be one of the main causes of preterm labor and has been associated with an adverse perinatal outcome in preterm infants. The controversy about the benefits/risks of delaying labor is a critical issue concerning the management of chorioamnionitis.
METHODS: The database between July 2001 and March 2006 was reviewed for women with singleton pregnancies between 22 and 28 weeks of gestation and with chorioamnionitis diagnosed on admission by amniotic fluid neutrophil elastase level. Women were classified according to the severity of chorioamnionitis (group A, amniotic fluid neutrophil elastase level of 0.15-1 microg/ml; B, 1-10 microg/ml; and C, > or = 10 microg/ml). During expectant management, serum C-reactive protein levels monitored the remission and aggravation of chorioamnionitis. Following deliveries, placentas were examined for histologic chorioamnionitis.
RESULTS: One hundred women were enrolled (group A, 38; B, 34; C, 28). The latency period until delivery was significantly longer in group A than in groups B and C. C-reactive protein levels just before delivery were higher than those on admission in 61% of the overall cases. Histologic chorioamnionitis and funisitis were manifested in 90.4% and 65.5%, respectively. Intrauterine fetal demise (4 cases) and neonatal and postneonatal deaths during admission (10 cases) were observed. Bronchopulmonary dysplasia was the most common major morbidity noted in groups B and C.
CONCLUSION: Chorioamnionitis could be controlled but is hard to cure. Higher levels of amniotic fluid neutrophil elastase are associated with a shorter interval from admission to delivery in women with subclinical chorioamnionitis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17364282     DOI: 10.1080/00016340601022793

Source DB:  PubMed          Journal:  Acta Obstet Gynecol Scand        ISSN: 0001-6349            Impact factor:   3.636


  6 in total

1.  Interpretation of amniotic fluid white blood cell count in "bloody tap" amniocenteses in women with symptoms of preterm labor.

Authors:  Sonya S Abdel-Razeq; Irina A Buhimschi; Mert O Bahtiyar; Victor A Rosenberg; Antonette T Dulay; Christina S Han; Erika F Werner; Stephen Thung; Catalin S Buhimschi
Journal:  Obstet Gynecol       Date:  2010-08       Impact factor: 7.661

2.  MATERNAL AND NEONATAL OUTCOMES OF HISTOLOGICAL CHORIOAMNIONITIS.

Authors:  A N Ocheke; I E Ocheke; P A Agaba; G E Imadde; O A Silas; O I Ajetunmobi; Eche John Godwins; C Ekere; A Sendeht; J Bitrus; E I Agaba; A S Sagay
Journal:  J West Afr Coll Surg       Date:  2016 Jul-Sep

3.  Diagnostic and Prognostic Value of Presepsin for Subclinical Chorioamnionitis in Pregnancies between 23-28 Week with Preterm Premature Rupture of the Membranes.

Authors:  Erbil Çakar; Şule Eren Çakar; Habibe Ayvacı Taşan; Deniz Karçaaltıncaba; Mehmet Baki Şentürk; Nermin Koç; Ramazan Uluhan
Journal:  Balkan Med J       Date:  2016-11-01       Impact factor: 2.021

4.  Chorioamnionitis (ChA) modifies CX3CL1 (fractalkine) production by human amniotic epithelial cells (HAEC) under normoxic and hypoxic conditions.

Authors:  Dariusz Szukiewicz; Jan Kochanowski; Tarun Kumar Mittal; Michal Pyzlak; Grzegorz Szewczyk; Krzysztof Cendrowski
Journal:  J Inflamm (Lond)       Date:  2014-05-13       Impact factor: 4.981

Review 5.  Perinatal Brain Injury As a Consequence of Preterm Birth and Intrauterine Inflammation: Designing Targeted Stem Cell Therapies.

Authors:  Madison C B Paton; Courtney A McDonald; Beth J Allison; Michael C Fahey; Graham Jenkin; Suzanne L Miller
Journal:  Front Neurosci       Date:  2017-04-10       Impact factor: 4.677

Review 6.  Understanding the Impact of Infection, Inflammation, and Their Persistence in the Pathogenesis of Bronchopulmonary Dysplasia.

Authors:  Jherna Balany; Vineet Bhandari
Journal:  Front Med (Lausanne)       Date:  2015-12-21
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.